Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765317000007/mck_10kx3312017.htm
August 2022
July 2022
May 2022
April 2022
April 2022
February 2022
February 2022
February 2022
January 2022
November 2021
Exhibit 99.1
McKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS
| Revenues of $48.7 billion for the fourth quarter and $198.5 billion for the full year, up 4% year-over-year. |
| Fourth-quarter GAAP earnings per diluted share from continuing operations of $16.79 and full-year GAAP earnings per diluted share from continuing operations of $23.28, up 137% year-over-year. |
| GAAP earnings per diluted share from continuing operations for the fourth quarter and full year include a pre-tax net gain of $3.9 billion, or $14.10 and $13.53 per diluted share, respectively, related to the previously announced creation of the Change Healthcare joint venture. |
| Excluding Cost Alignment Plan charges of three cents from Adjusted Earnings, fourth-quarter results per diluted share of $3.42, up 8% year-over-year, compared to $3.18 in the prior year. |
| Excluding Cost Alignment Plan charges of four cents and the second-quarter goodwill impairment charge of $1.26 from Adjusted Earnings, full-year results per diluted share of $12.91, up 3% year-over-year, compared to $12.52 in the prior year. |
| Fiscal 2017 cash flow from operations of $4.7 billion, up 29% year-over-year. |
| In connection with issuing our Fiscal 2018 Outlook, we have revised our definition of Adjusted Earnings. |
SAN FRANCISCO, May 18, 2017 McKesson Corporation (NYSE:MCK) today reported that revenues for the fourth quarter ended March 31, 2017, were $48.7 billion, up 4% compared to $46.7 billion a year ago. On a constant currency basis, revenues increased 5% over the prior year. For the fiscal year, McKesson had revenues of $198.5 billion, up 4% compared to $190.9 billion a year ago. On a constant currency basis, revenues increased 5% over the prior year.
On the basis of U.S. generally accepted accounting principles (GAAP), fourth-quarter earnings per diluted share from continuing operations was $16.79, compared to $1.97 a year ago. Full-year GAAP earnings per diluted share from continuing operations was $23.28 compared to $9.84 a year ago, up 137% year-over-year.
1
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765317000007/mck_10kx3312017.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Mckesson Corp.
Mckesson Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:
Rating
Learn More![]()
We consider an accounting estimate to be critical if the estimate requires us to make assumptions about matters that were uncertain at the time the accounting estimate was made and if different estimates that we reasonably could have used in the current period, or changes in the accounting estimate that are reasonably likely to occur from period to period, could have a material impact on our financial condition or results from operations.
Any material changes in key assumptions, including failure to meet business plans, negative changes in government reimbursement rates, deterioration in the U.S. and global financial markets, an increase in interest rate or an increase in the cost of equity financing by market participants within the industry or other unanticipated events and circumstances, may decrease the projected cash flows or increase the discount rates and could potentially result in an impairment charge.
Gross profit margin over the last two years was favorably affected by benefits from our global procurement arrangements and higher cash receipts representing our share of antitrust legal settlements.
Excluding the gain on Healthcare Technology Net Asset Exchange, this segments operating expenses increased primarily due to a non-cash pre-tax charge of $290 million $282 million after-tax for the EIS goodwill impairment charge, partially offset by cost savings from the 2016 cost alignment plan and ongoing cost management efforts and one less month of expenses from the Core MTS Business.
operating expenses benefited from lower restructuring charges and cost savings associated with a cost alignment plan implemented in the fourth quarter of 2016 and ongoing expense management efforts.
Distribution Solutions: Operating profit margin...Read more
Gross profit margin for 2016...Read more
Gross profit margin decreased in...Read more
Buy margin primarily reflects volume...Read more
Corporate expenses decreased 17% in...Read more
A further decrease in the...Read more
Operating expenses decreased in 2017...Read more
Our ongoing consideration of all...Read more
Operating expenses and operating expenses...Read more
operating expenses decreased primarily due...Read more
Other estimates inherent in both...Read more
This segments gross profit margin...Read more
Acquisition expenses and related adjustments...Read more
Operating expense decreased in 2016...Read more
Distribution Solutions segments gross profit...Read more
Excluding the gain on Healthcare...Read more
Amortization expense for 2016 decreased...Read more
These decreases were partially offset...Read more
At March 31, 2017, the...Read more
Upon the effectiveness of the...Read more
operating profit benefited from lower...Read more
Gross profit decreased 1% in...Read more
Corporate: Corporate expenses, net, decreased...Read more
Excluding unfavorable foreign currency effects...Read more
Excluding unfavorable foreign currency effects...Read more
The decline in estimated future...Read more
Gross profit decreased 1% in...Read more
operating expenses were favorably affected...Read more
Technology Solutions segments gross profit...Read more
The Companys Board has authorized...Read more
Gross profit margin decreased in...Read more
Gross profit margin for 2017...Read more
Our Celesio reporting unit within...Read more
Indicators that are considered include...Read more
We disclose intervening events at...Read more
Corporate expenses for 2017 also...Read more
The 2016 cost alignment plan...Read more
We anticipate the 2016 cost...Read more
Operating activities over the last...Read more
As a result, a net...Read more
North America pharmaceutical distribution and...Read more
Consolidated working capital increased at...Read more
Revenues for 2017 also increased...Read more
Estimated remaining charges primarily consist...Read more
In discussing our operating results,...Read more
Goodwill and Intangible Assets: As...Read more
A material default in payment,...Read more
Technology Solutions: Operating profit and...Read more
Technology Solutions segments operating expenses...Read more
At March 31, 2017, the...Read more
These factors could make our...Read more
In 2015, we committed to...Read more
For U.S. GAAP purposes, the...Read more
Operating profit and operating profit...Read more
Interest expense decreased in 2016...Read more
These increases were partially offset...Read more
Amortization expenses increased in 2017...Read more
However, there can be no...Read more
Additionally, as required under the...Read more
While this transaction was predominantly...Read more
Operating profit and operating profit...Read more
During 2017, 2016 and 2015,...Read more
An increase or decrease in...Read more
Currently, all of our intangible...Read more
Corporate expenses, net increased in...Read more
Medical-Surgical distribution and services revenues...Read more
The redemption value is the...Read more
Operating expenses decreased 47% and...Read more
Operating expenses for 2017 and...Read more
Revenues increased in 2017 primarily...Read more
Changes to any of the...Read more
Consolidated working capital decreased at...Read more
However, the likelihood of a...Read more
As a result, we continuously...Read more
Additionally, we are obligated to...Read more
These assumptions require significant judgment...Read more
The transferor entity recognized a...Read more
We believe that our operating...Read more
If our current estimate of...Read more
Determining the useful life of...Read more
operating expenses benefited from a...Read more
Operating Expenses Excluding Gain on...Read more
Our North America distribution business...Read more
Excluding favorable foreign currency effects...Read more
Excluding favorable foreign currency effects...Read more
Technology Solutions segments operating profit...Read more
In estimating future taxable income,...Read more
Assumptions and estimates about future...Read more
Gain on Healthcare Technology Net...Read more
excludes the pre-tax gain on...Read more
Gain on Healthcare Technology Net...Read more
New accounting pronouncements that we...Read more
For intangible assets, we typically...Read more
Deferred tax liabilities have been...Read more
Gain on Change Healthcare Net...Read more
On April 3, 2017, we...Read more
An increase or decrease of...Read more
In addition, we may access...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Mckesson Corp provided additional information to their SEC Filing as exhibits
Ticker: MCK
CIK: 927653
Form Type: 10-K Annual Report
Accession Number: 0000927653-17-000007
Submitted to the SEC: Mon May 22 2017 4:43:21 PM EST
Accepted by the SEC: Mon May 22 2017
Period: Friday, March 31, 2017
Industry: Wholesale Drugs Proprietaries And Druggists Sundries